SecBot SecBot
PRESS-RELEASE ·Filed Nov 4, 2026

DNTH

Dianthus Therapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed12d 6h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Watch for Phase 2 MoMeNtum top-line results in December 2026, which will be a key catalyst for the MMN program. The CIDP CAPTIVATE Part A results by YE'27 and gMG EMERGE results in 2H'28 are longer-term milestones. The $1.2B cash runway into 2030 removes near-term financing risk.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$83.01
T+0 close · Nov 4, 2026 · via day close
Latest settled
+11.41%
T+5 · $92.48 · next T+20 in 17d
Vs SPY
+8.12%
α at T+5
Latest observation
+6.17%
T+6 · FF3 residual α
  1. T+0 · Nov 5 $83.01entry
  2. T+1 · 11d ago +3.64%α +3.33% · $86.03
  3. T+5 · 5d ago +11.41%α +8.12% · $92.48
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dianthus Therapeutics reported Q3 2026 net loss of $46.6M ($0.81 per share), wider than the $36.8M loss in Q3 2025, but the EPS of -$0.81 beat the consensus estimate of -$0.95. The company highlighted strong clinical progress across its pipeline, including a 75% response rate in the CIDP Phase 3 CAPTIVATE trial interim analysis and a $1.2B cash runway into 2030.

Key Financial Metrics

EPS
−$0.81
est −$0.95 · +14.7%
Revenue
$1.2M
est $389.0K · +211.1% · +205.6% YoY
Rating
beat

Key Facts

  • Q3 2026 net loss of $46.6M ($0.81 per share) vs $36.8M ($0.97 per share) in Q3 2025
  • EPS of -$0.81 beat consensus estimate of -$0.95
  • Revenue of $1.21M (license revenue) vs $396K in Q3 2025, well above $389K consensus
  • Cash, cash equivalents and investments of ~$1.2B as of Sep 30, 2026, providing runway into 2030
  • Phase 3 CAPTIVATE trial in CIDP showed 75% response rate in interim analysis of first 40 participants
  • Phase 2 MoMeNtum trial in MMN top-line results expected December 2026
  • Phase 3 EMERGE trial in gMG on track with top-line results expected 2H'28
  • R&D expenses increased to $45.6M from $32.5M YoY, driven by clinical costs and headcount

Financial Impact

Net loss of $46.6M in Q3 2026, wider than $36.8M in Q3 2025; cash burn rate increased with R&D spend up 40% YoY

net losscash positionR&D expensesG&A expenses

Risk Factors

  • Clinical-stage biotech with no approved products; all programs are investigational
  • Phase 3 CAPTIVATE interim analysis based on only 40 patients; results may not be predictive of full trial
  • Increasing R&D and G&A expenses driving wider net losses
  • Pipeline relies on successful clinical trial execution across multiple indications

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (24 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3395769

Track record

23 reports on DNTH

Performance horizon

7 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
  2. Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 4/10 No price data
  4. Nov 4, 202612d ago Press Release Neutral 4/10 Viewing Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
  5. Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
  6. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
  7. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
  8. Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
  9. Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
  10. Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (10h 42m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026